Aclarion, Inc. (ACON): Nasdaq/NYSE listing notice — Aclarion files delayed Q2 10-Q after Nasdaq notice; believes compliance regained

Aclarion, Inc.

Received Nasdaq notice on August 23, 2023 for non-compliance with Listing Rule 5250(c)(1) due to late 10-Q.
Delay caused by completion of review process by new independent accountant CohnReznick LLP.
Filed the delinquent Quarterly Report for Q2 2023 on August 25, 2023.
Company believes it has regained compliance; Nasdaq notice had no immediate effect on trading.
If not resolved, company would have had until October 22, 2023 to submit a compliance plan.

item 2.02 item 8.01 item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aclarion, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

August 23, 2023, the Company received a notice from Nasdaq notifying the Company that because the Company remains delinquent in filing its Form 10-Q, the Company no longer complies with Nasdaq Listing Rule 5250(c)(1), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The notice received from Nasdaq has no immediate effect on the listing or trading of the Company’s securities on Nasdaq. However, if the Company would fail to timely regain compliance with Rule 5250(c)(1), the Company’s securities would be subject to delisting from

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Aclarion, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-006083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.